Sep. 15, 2014, 12:48 PM
- Diagnostics maker Alere (ALR +12.9%) bucks biotech's down day by jumping on a 6x surge in volume on reports that former CEO Ron Zwanziger intends to bid $46 per share for the company. His potential offer would value Alere at almost $4B.
- Mr. Zwanziger believes the firm is undervalued. He has a point. Alere's sales and earnings are decelerating and its P/S, P/B and P/CF ratios all lag the industry according to msn money.
Jun. 10, 2013, 7:54 AMMore on Coppersmith-Alere (ALR) letter: Coppersmith wants Alere to use the proceeds from any sales to slash its debt, which is almost $3.8B vs a market cap of $2.15B. The ops that Coppersmith wants Alere to sell are its health care management unit, its consumer products joint venture with P&G (PG), and possibly its toxicology unit. Coppersmith has been agitating for change since last month and has nominated three directors to Alere's board. | Comment!
ALR vs. ETF Alternatives
Alere Inc enables individuals to take charge of improving their health and quality of life at home. The Company operates in three segments; professional diagnostics, health information solutions and consumer diagnostics.
Other News & PR